Esomust-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Esomeprazole 40mg, indicated for the management of gastroesophageal reflux disease (GERD), acid peptic disorders, and related gastrointestinal motility disturbances. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric emptying and enhances gastrointestinal motility, thereby alleviating symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting mucosal healing and symptom relief in acid-related disorders. The synergistic action of these agents provides effective control of acid reflux symptoms while improving gastric motility, making Esomust-DSR suitable for patients with delayed gastric emptying and erosive esophagitis. It is recommended to be administered orally, preferably before meals, under medical supervision. Caution is advised in patients with known hypersensitivity to either component, hepatic impairment, or cardiac arrhythmias. Potential side effects may include headache, dry mouth, abdominal discomfort, and rare extrapyramidal symptoms. Esomust-DSR Capsule should be used as part of a comprehensive treatment plan, including lifestyle modifications, to optimize therapeutic outcomes in acid peptic disease management.